🟢 Kura Oncology is trading 5% up today amid broader biotech-sector strength

Kura Oncology is trading at $9.83, up 5.07%, amid broader biotech-sector strength; no company-specific catalyst has been identified.

• No clear October 20 company-specific announcement was identified; Kura Oncology’s investor-relations page lists an October 2 release as its latest press release.
• XBI was reported up about 2%.
• Merck KGaA’s announced acquisition of Silence Therapeutics added to sector M&A activity, but this does not confirm the deal directly caused Kura Oncology’s gain.